

Supplementary Materials

# **Safety and Efficacy of Direct Oral Anticoagulants versus Warfarin in Patients with Obesity and Venous Thromboembolism: A Retrospective Analysis**

**Zoe H. Tu, PharmD<sup>1</sup>; Alejandro D. Perez<sup>2</sup>; Thomas E. Diaz, BA<sup>2</sup>; Matthew S. Loop, PhD<sup>3</sup>; Megan Clarke, PharmD<sup>4</sup>**

<sup>1</sup>Department of Pharmacy, Houston Methodist Hospital, Houston, Texas

<sup>2</sup>University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina

<sup>3</sup>Department of Health Outcomes and Research and Policy, Auburn University Harrison College of Pharmacy, Auburn, Alabama


<sup>4</sup>Department of Pharmacy, Novant Health New Hanover Regional Medical Center, Wilmington, North Carolina

**Citation:** *Tex Heart Inst J.* 2024;51(1):e238260. doi: 10.14503/THIJ-23-8260


**Corresponding author:**

Zoe Tu, 2910 Milam St, Apt 1128, Houston, TX, 77006 ([zhtu@houstonmethodist.org](mailto:zhtu@houstonmethodist.org))


Supplemental Figure 1 – Plot of the Test for Proportional Hazards: Thromboembolic Events (DOAC vs Warfarin)



Supplemental Figure 2 – Plot of the Test for Proportional Hazards: Bleeding Events Requiring Hospitalization (DOAC vs Warfarin)




Supplemental Figure 3 – Forest Plot for Thromboembolic Events



\*DOAC = 1, warfarin = 0

Supplemental Figure 4 – Forest Plot for Bleeding Events Requiring Hospitalization



\*DOAC = 1, warfarin = 0

### Supplemental Table I – Baseline Demographics Pre- and Post-Propensity Score Matching

Before:

Characteristics	DOAC (n = 520)	Warfarin (n = 267)	Mean Difference
Age, y	54.9	54.2	0.045
Male, n (%)	230 (44.2)	120 (44.9)	-0.014
<b>Race</b>			
White, n (%)	332 (63.8)	152 (57)	0.14
Other, n (%)	188 (36.2)	115 (43.1)	-0.14
<b>Baseline Clinical Characteristics</b>			
BMI, kg/m <sup>2</sup>	44.3	46.9	-0.27
CKD, n (%)	75 (14.2)	46 (17.2)	-0.074
History of VTE, n (%)	119 (22.9)	67 (25.1)	-0.05

\*Continuous variables reported as mean

After:

Characteristics	DOAC (n = 267)	Warfarin (n = 267)	Mean Difference
Age, y	54.3	54.2	0.0056
Male, n (%)	120 (45)	120 (45)	0
<b>Race</b>			
White, n (%)	146 (54.7)	152 (56.9)	-0.045
Other, n (%)	38 (14.2)	115 (43.1)	0.045
<b>Baseline Clinical Characteristics</b>			
BMI, kg/m <sup>2</sup>	46	46.9	-0.09
CKD, n (%)	53 (19.9)	46 (17.2)	0.069
History of VTE, n (%)	70 (26.2)	67 (25.1)	0.026

\*Continuous variables reported as mean